These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 31599866)
1. Glucagon nasal powder (Baqsimi) for severe hypoglycemia. Med Lett Drugs Ther; 2019 Sep; 61(1581):148-149. PubMed ID: 31599866 [No Abstract] [Full Text] [Related]
2. Dasiglucagon (Zegalogue) for severe hypoglycemia. Med Lett Drugs Ther; 2021 Aug; 63(1631):132-134. PubMed ID: 34544102 [No Abstract] [Full Text] [Related]
3. In brief: A new glucagon injection (Gvoke) for severe hypoglycemia. Med Lett Drugs Ther; 2019 Nov; 61(1585):186. PubMed ID: 31770360 [No Abstract] [Full Text] [Related]
4. Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia. Giménez M; Khunti K; Matsuhisa M; Chenji S; Syring K; Yan Y Diabetes Ther; 2023 Nov; 14(11):1757-1769. PubMed ID: 37707700 [TBL] [Abstract][Full Text] [Related]
5. Intranasal Glucagon for Severe Hypoglycemia. Grant JS; Graven LJ Home Healthc Now; 2017 Feb; 35(2):114-115. PubMed ID: 28157777 [No Abstract] [Full Text] [Related]
6. Glucagon: Delivery advancements for hypoglycemia management. Kumar S; Sanap SN; Pandey P; Khopade A; Sawant KK Int J Pharm; 2024 Mar; 652():123785. PubMed ID: 38224759 [TBL] [Abstract][Full Text] [Related]
7. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Sherr JL; Ruedy KJ; Foster NC; Piché CA; Dulude H; Rickels MR; Tamborlane WV; Bethin KE; DiMeglio LA; Fox LA; Wadwa RP; Schatz DA; Nathan BM; Marcovina SM; Rampakakis E; Meng L; Beck RW; Diabetes Care; 2016 Apr; 39(4):555-62. PubMed ID: 26884472 [TBL] [Abstract][Full Text] [Related]
8. Intranasal glucagon: a promising approach for treatment of severe hypoglycemia. Pontiroli AE J Diabetes Sci Technol; 2015 Jan; 9(1):38-43. PubMed ID: 25385946 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia. Pontiroli AE; Tagliabue E Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31349701 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578 [TBL] [Abstract][Full Text] [Related]
11. Intranasal versus injectable glucagon for hypoglycemia in type 1 diabetes: systematic review and meta-analysis. Pontiroli AE; Tagliabue E Acta Diabetol; 2020 Jun; 57(6):743-749. PubMed ID: 32025860 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Usability of Intranasal Glucagon for the Management of Hypoglycemia in Patients With Diabetes: A Systematic Review. Singh-Franco D; Moreau C; Levin AD; Rosa D; Johnson M Clin Ther; 2020 Sep; 42(9):e177-e208. PubMed ID: 32873417 [TBL] [Abstract][Full Text] [Related]
13. Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Guzman CB; Dulude H; Piché C; Rufiange M; Sadoune AA; Rampakakis E; Carballo D; Triest M; Zhang MX; Zhang S; Tafreshi M; Sicard E Diabetes Obes Metab; 2018 Mar; 20(3):646-653. PubMed ID: 29053231 [TBL] [Abstract][Full Text] [Related]
14. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Seaquist ER; Dulude H; Zhang XM; Rabasa-Lhoret R; Tsoukas GM; Conway JR; Weisnagel SJ; Gerety G; Woo VC; Zhang S; Carballo D; Pradhan S; Piché CA; Guzman CB Diabetes Obes Metab; 2018 May; 20(5):1316-1320. PubMed ID: 29504662 [TBL] [Abstract][Full Text] [Related]
15. Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus. Stenninger E; Aman J Diabetologia; 1993 Oct; 36(10):931-5. PubMed ID: 8243872 [TBL] [Abstract][Full Text] [Related]
16. Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study. Yale JF; Dulude H; Egeth M; Piché CA; Lafontaine M; Carballo D; Margolies R; Dissinger E; Shames AR; Kaplowitz N; Zhang MX; Zhang S; Guzman CB Diabetes Technol Ther; 2017 Jul; 19(7):423-432. PubMed ID: 28556672 [TBL] [Abstract][Full Text] [Related]
17. Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality? Pontiroli AE; Ceriani V Diabetes Obes Metab; 2018 Aug; 20(8):1812-1816. PubMed ID: 29652110 [TBL] [Abstract][Full Text] [Related]
18. Intranasal Glucagon: A New Way to Treat Hypoglycemic Emergencies. Lowe RN; Trujillo JM Ann Pharmacother; 2020 Aug; 54(8):780-787. PubMed ID: 32052651 [No Abstract] [Full Text] [Related]
19. Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon Versus Lyophilized Glucagon in Type 1 Diabetes Subjects. Castle JR; Youssef JE; Branigan D; Newswanger B; Strange P; Cummins M; Shi L; Prestrelski S J Diabetes Sci Technol; 2016 Sep; 10(5):1101-7. PubMed ID: 27325390 [TBL] [Abstract][Full Text] [Related]
20. Needle-free nasal delivery of glucagon for treatment of diabetes-related severe hypoglycemia: toxicology of polypropylene resin used in delivery device. Reno FE; Edwards CN; Bendix Jensen M; Török-Bathó M; Esdaile DJ; Piché C; Triest M; Carballo D Cutan Ocul Toxicol; 2016 Sep; 35(3):242-7. PubMed ID: 26426957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]